The Latest Parkinsons Disease Industry Statistics Explained
Parkinson’s Drugs Market worth $5.69 billion by 2022,
The statistic “Parkinson’s Drugs Market worth $5.69 billion by 2022” refers to the projected value of the global market for pharmaceutical drugs used in the treatment and management of Parkinson’s disease by the year 2022. This figure represents the estimated total revenue that is expected to be generated from the sales of Parkinson’s drugs worldwide, reflecting the significant demand and growth within the market. Factors contributing to this valuation may include an increase in the prevalence of Parkinson’s disease, advancements in drug development and technology, as well as the growing aging population. The statistic underscores the economic significance and importance of addressing the treatment needs of individuals living with Parkinson’s disease.
North America likely to drive growth of the market with a CAGR of 5.8% by 2027,
The statistic “North America likely to drive growth of the market with a CAGR of 5.8% by 2027” indicates that the North American region is projected to experience a Compound Annual Growth Rate (CAGR) of 5.8% in terms of market expansion until the year 2027. This suggests that North America is expected to be a significant contributor to the overall growth of the market during this period, outpacing other regions. Factors such as a strong economy, technological advancements, favorable regulatory environment, and increasing consumer demand are likely driving this growth trend. It implies that businesses operating in North America or targeting the region may have promising growth opportunities and should consider investing resources to capitalize on this projected market expansion.
The global Parkinson’s disease market was valued at $4.08 billion in 2017,
This statistic indicates the total value of the Parkinson’s disease market worldwide in the year 2017 was $4.08 billion. This value represents the sum of all revenues generated from the sale of medications, medical devices, services, and other products related to Parkinson’s disease. The size of the market reflects the demand for treatments and therapies for individuals affected by Parkinson’s disease on a global scale. Factors such as prevalence of the disease, advancements in medical technology, and overall healthcare spending can influence the market value. Understanding the market size is crucial for stakeholders, including pharmaceutical companies, healthcare providers, and policymakers, to assess the impact of Parkinson’s disease and develop strategies to address the needs of patients and improve outcomes.
European markets projected to grow steadily between 2018 and 2026 due to rising patient awareness,
The statistic that European markets are projected to grow steadily between 2018 and 2026 due to rising patient awareness suggests that the healthcare sector in Europe is expected to experience a positive and consistent growth trajectory over this time period. This growth is attributed to an increasing awareness among patients about healthcare services and products, leading to higher demand in the market. As patients become more informed and proactive about their health, they are likely to seek out and utilize a wider range of healthcare solutions, driving market expansion. This trend signifies opportunities for healthcare companies in Europe to enhance their offerings and expand their market presence to meet the growing needs of an engaged patient population.
The challenging diagnosis of Parkinson’s results in up to 25% of patients misdiagnosed, contributing to the market,
The statistic suggests that the diagnosis of Parkinson’s disease is often challenging, leading to misdiagnosis in a significant proportion of patients, estimated at up to 25%. This high rate of misdiagnosis can have several implications, including delays in receiving appropriate treatment, unnecessary medications, and potential psychological distress for patients. Furthermore, these misdiagnoses can also impact the healthcare market, as resources may be allocated inefficiently towards treating conditions that patients do not actually have. Improving the accuracy of Parkinson’s diagnosis through advanced diagnostic tools and expert evaluation is crucial in reducing the negative impact of misdiagnosis on patients and the broader healthcare system.
The carbidopa and levodopa combination segment dominated over half of the Parkinson’s disease drugs market in 2020,
The statistic indicates that the carbidopa and levodopa combination was the most widely used treatment in the Parkinson’s disease drugs market in 2020, accounting for more than half of the market share. This suggests that carbidopa and levodopa combination therapy is highly trusted and preferred by physicians and patients for managing the symptoms of Parkinson’s disease. This dominance could be attributed to the effectiveness of the combination in alleviating motor symptoms and improving the quality of life for individuals with Parkinson’s disease. It also highlights the significance of this particular treatment option in the healthcare industry and the substantial impact it has on the management of Parkinson’s disease.
The dopamine agonists segment accounted for over a third of the market’s revenue,
This statistic indicates that the revenue generated by the dopamine agonists segment constitutes more than one-third of the total market revenue in the given context. Dopamine agonists are a type of medication that specifically targets dopamine receptors in the brain, commonly used in the treatment of conditions such as Parkinson’s disease and restless legs syndrome. The fact that this segment accounts for over a third of the market revenue suggests that dopamine agonists are a significant contributor to the overall financial performance of the market, highlighting their prominence and importance in the pharmaceutical industry or relevant market sector. This statistic indicates the relative market share and financial impact of dopamine agonists compared to other products or segments within the market.
Asia-Pacific is predicted to record a high CAGR in Parkinson’s market due to increasing prevalence of the disease,
The statistic indicates that the Asia-Pacific region is expected to experience a high compound annual growth rate (CAGR) in the Parkinson’s disease market. This anticipated growth is attributed to the rising prevalence of Parkinson’s disease in the region. The increasing number of individuals affected by Parkinson’s disease in Asia-Pacific creates a larger market demand for related drugs, treatments, and healthcare services, thus driving growth in the Parkinson’s market. Factors such as aging populations, lifestyle changes, and improved diagnostic capabilities may all contribute to the higher prevalence of Parkinson’s disease in the region, leading to the projected increase in the market CAGR.
Pharmaceutical companies are trying to access the emerging markets of India and China, which in 2019 showed a CAGR of 9.3%,
This statistic indicates that pharmaceutical companies are strategically targeting the rapidly growing markets in India and China, with both countries demonstrating a Compounded Annual Growth Rate (CAGR) of 9.3% in 2019. The significant growth rate suggests a promising opportunity for pharmaceutical companies to expand their operations and reach a larger customer base in these emerging markets. By tapping into the markets of India and China, pharmaceutical companies can capitalize on the increasing demand for healthcare products and services, as well as leverage the growing economies of these countries to drive sales and revenue growth. This statistic underscores the importance for pharmaceutical companies to focus on emerging markets to achieve sustainable business growth in the industry.
Growing number of geriatric population and technological advancement in medical devices facilities drives the Parkinson’s disease treatment market,
The statistic indicates that the Parkinson’s disease treatment market is experiencing growth due to two main factors: the increasing geriatric population and technological advancements in medical devices. The aging population is more susceptible to Parkinson’s disease, a neurological disorder that commonly affects older adults. As the number of elderly individuals grows, so does the demand for effective treatment options for Parkinson’s disease. Furthermore, advancements in medical technology have led to the development of innovative devices and therapies that can improve the management and treatment of the disease. These factors combined are driving the expansion of the Parkinson’s disease treatment market, offering new opportunities for addressing the needs of patients and improving their quality of life.
More than 10 million people worldwide are living with Parkinson’s disease, contributing to the market,
The statistic that more than 10 million people worldwide are living with Parkinson’s disease signifies a significant public health concern that impacts individuals globally. Parkinson’s disease is a progressive neurological disorder that affects movement, leading to symptoms such as tremors, stiffness, and difficulty with balance and coordination. This high number of individuals living with Parkinson’s disease underscores the need for continued research, treatment options, and support services for patients, caregivers, and healthcare providers. Additionally, the prevalence of Parkinson’s disease also has economic ramifications, as it contributes to the demand for medical services, medications, and other related therapies in the healthcare market. Efforts to improve early detection, enhance treatment strategies, and ultimately find a cure for Parkinson’s disease are crucial in addressing the challenges faced by those affected by this condition.
Oral drug therapy segment dominated the Parkinson’s disease treatment market with over 60% share in 2019,
The statistic “Oral drug therapy segment dominated the Parkinson’s disease treatment market with over 60% share in 2019” indicates that within the Parkinson’s disease treatment market, the use of oral medications was the most widely utilized form of therapy, accounting for more than 60% of all treatments in 2019. This suggests that healthcare providers and patients favored oral drug therapy as the primary method of managing Parkinson’s disease symptoms during that time. This information is valuable for stakeholders in the healthcare industry, as it demonstrates the significant preference for oral medications in treating Parkinson’s disease and highlights the importance of continued research and development in this area to improve patient outcomes.
62.8% of people suffering from Parkinson’s are above the age of 60, market research required to cater to this demographic,
The statistic that 62.8% of people suffering from Parkinson’s are above the age of 60 indicates a significant portion of the Parkinson’s population falls within the elderly demographic. This finding suggests a need for market research aimed at understanding and catering to the specific needs and preferences of this older age group affected by Parkinson’s. Targeted market research could help identify potential products, services, or interventions that could improve the quality of life for older individuals living with Parkinson’s, such as specialized mobility aids, assistive technologies, or healthcare services tailored to their unique challenges and circumstances. By focusing on this demographic, businesses and organizations can better meet the needs of individuals with Parkinson’s and enhance their overall well-being.
The use of smartphone applications for monitoring Parkinson’s disease can help reduce clinic visits, leading to cost savings in healthcare,
The statistic suggests that utilizing smartphone applications for monitoring Parkinson’s disease can result in a reduction of clinic visits, ultimately translating to cost savings in healthcare. By using these applications, patients and healthcare providers can remotely monitor the progression of the disease, track symptoms, and potentially detect any changes in real-time. This proactive and remote monitoring can lead to earlier interventions, better management of the disease, and a decrease in the number of in-person clinic visits required. As a result, the overall cost of care for individuals with Parkinson’s disease can be reduced, making healthcare more efficient and potentially improving patient outcomes.
Apomorphine is expected to witness substantial growth over the forecast period in the Parkinson’s disease market.
The statement suggests that researchers and market analysts anticipate a significant increase in the use and demand for apomorphine within the Parkinson’s disease market over the specified forecast period. This growth could be driven by several factors such as the drug’s effectiveness in managing symptoms of Parkinson’s disease, rising awareness among physicians and patients about its benefits, and potentially new applications or formulations that may contribute to the expansion of its market share. The expected growth in apomorphine usage indicates a positive trend for both the pharmaceutical industry and patients with Parkinson’s disease, highlighting the potential for increased access to an important treatment option in the management of this neurological condition.
Parkinson’s Disease patient costs affecting drug market, average out-of-pocket costs for Parkinson’s Disease Treatment was $2,500 per year in the US.
This statistic indicates that the average out-of-pocket costs for Parkinson’s Disease treatment in the United States amount to $2,500 per year. These costs are incurred by patients receiving treatment for Parkinson’s Disease and can have a significant impact on the overall economic burden faced by both the patients and the healthcare system. The high out-of-pocket costs for Parkinson’s Disease treatment highlight the financial challenges that patients may face in managing their condition and accessing necessary care. Furthermore, these costs can also influence the dynamics of the drug market for Parkinson’s Disease treatments, as patients may be limited in their ability to afford or adhere to prescribed medications due to financial constraints.
References
0. – https://www.www.prnewswire.com
1. – https://www.davidson.weizmann.ac.il
2. – https://www.parkinsonsnewstoday.com
3. – https://www.www.infiniumglobalresearch.com
4. – https://www.www.mccourier.com
5. – https://www.www.marketsandmarkets.com
6. – https://www.www.parkinson.org
7. – https://www.www.alliedmarketresearch.com
8. – https://www.www.expertmarketresearch.com
9. – https://www.www.psmarketresearch.com
10. – https://www.www.fortunebusinessinsights.com
11. – https://www.www.researchandmarkets.com
12. – https://www.www.giiresearch.com
